Literature DB >> 14695093

Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.

Narong Ponsa1, Jetsumon Sattabongkot, Pattamaporn Kittayapong, Nantana Eikarat, Russell E Coleman.   

Abstract

The sporontocidal activity of tafenoquine (WR-238605) and artelinic acid was determined against naturally circulating isolates of Plasmodium vivax in western Thailand. Primaquine was used as a negative control and a dihydroacridine-dione (WR-250547) was used as a positive control. Laboratory-reared Anopheles dirus mosquitoes were infected with P. vivax by allowing mosquitoes to feed on blood (placed in an artificial-membrane feeding apparatus) collected from gametocytemic volunteers reporting to local malaria clinics in Tak province, Thailand. Four days post-infection, mosquitoes were refed on uninfected mice treated 90 minutes earlier with a given drug. Drug activity was determined by assessing oocyst and sporozoite development. Neither primaquine nor artelinic acid affected oocyst or sporozoite development at a dose of 100 mg of base drug/kg of mouse body weight. In contrast, tafenoquine and WR-250547 affected sporogonic development at doses as low as 25.0 and 0.39 mg/kg, respectively. The potential role of these compounds in the prevention of malaria transmission is discussed, as are alternative strategies for the use of transmission-blocking antimalarial drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695093

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.

Authors:  Sophie H Adjalley; Geoffrey L Johnston; Tao Li; Richard T Eastman; Eric H Ekland; Abraham G Eappen; Adam Richman; B Kim Lee Sim; Marcus C S Lee; Stephen L Hoffman; David A Fidock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 3.  Tafenoquine and G6PD: a primer for clinicians.

Authors:  Cindy S Chu; David O Freedman
Journal:  J Travel Med       Date:  2019-06-01       Impact factor: 8.490

Review 4.  Modern malaria chemoprophylaxis.

Authors:  G Dennis Shanks; Michael D Edstein
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi.

Authors:  Yudi T Pinilla; Stefanie C P Lopes; Vanderson S Sampaio; Francys S Andrade; Gisely C Melo; Alessandra S Orfanó; Nágila F C Secundino; Maria G V B Guerra; Marcus V G Lacerda; Kevin C Kobylinski; Karin S Escobedo-Vargas; Victor M López-Sifuentes; Craig A Stoops; G Christian Baldeviano; Joel Tarning; Gissella M Vasquez; Paulo F P Pimenta; Wuelton M Monteiro
Journal:  PLoS Negl Trop Dis       Date:  2018-02-14

6.  NPC1161B, an 8-Aminoquinoline Analog, Is Metabolized in the Mosquito and Inhibits Plasmodium falciparum Oocyst Maturation.

Authors:  Timothy Hamerly; Rebecca E Tweedell; Bernadette Hritzo; Vincent O Nyasembe; Babu L Tekwani; N P Dhammika Nanayakkara; Larry A Walker; Rhoel R Dinglasan
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

Review 7.  The role of anti-malarial drugs in eliminating malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

8.  Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.

Authors:  Qigui Li; Michael O'Neil; Lisa Xie; Diana Caridha; Qiang Zeng; Jing Zhang; Brandon Pybus; Mark Hickman; Victor Melendez
Journal:  Malar J       Date:  2014-04-14       Impact factor: 2.979

Review 9.  Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Authors:  Yehenew A Ebstie; Solomon M Abay; Wondmagegn T Tadesse; Dawit A Ejigu
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162

10.  Relapses of Plasmodium vivax malaria threaten disease elimination: time to deploy tafenoquine in India?

Authors:  Sundus Shafat Ahmad; Manju Rahi; Amit Sharma
Journal:  BMJ Glob Health       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.